Fredrik Landström

Fredrik Landström

Auto-generated profile, based on publicly available information

Fredrik Landström

Department of Otolaryngology, Örebro University Hospital, Örebro, Sweden

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2010 in Dermatologic Surgery
Verified
Journal Article
Closed access
PDF file
FLFredrik J. Landström
Fredrik J. Landström
CNChrister O.S. Nilsson
Christer O.S. Nilsson
SCSven Crafoord
Sven Crafoord
JRJohan A. Reizenstein
Johan A. Reizenstein
GAGun-Britt M. Adamsson
Gun-Britt M. Adamsson
LLLennart A. Löfgren
Lennart A. Löfgren

10 June 2015 in Acta Oto-Laryngologica
Verified
Journal Article
Closed access
PDF file
FLFredrik J. Landström
Fredrik J. Landström
JRJohan Reizenstein
Johan Reizenstein
GAGun-Britt Adamsson
Gun-Britt Adamsson
MBMathias von Beckerath
Mathias von Beckerath
CMClaes Möller
Claes Möller
Conclusion: ECT can be a safe curative mono modality treatment, especially in tongue cancer. The future role for ECT in head and neck cancer needs to be further investigated. Introduction: Electrochemotherapy (ECT) is a cancer treatment modality that uses electroporation to increase the intracellular accumulation of hydrophilic chemotherapeutic drugs, especially bleomycin. Objectives: To report the 5-year local tumor control, safety of treatment and survival after ECT, and the 1-year quality-of-life (QoL) data. Materials and methods: Nineteen patients with primary head and neck cancer were included and treated with ECT with curative intent. All except one patient had squamous cell carcinoma (SCC). Radiotherapy (RT) was performed in all patients with SCC and tumor infiltration ≥5 mm. The EORTC H&N 35 questionnaire was used at baseline and 12 months after treatment. The Wilcoxon signed rank test and McNemar’s test were used for paired data and Mann Whitney U-test and Fishers exact test were used for independent data (sub-group comparison). Results: There were no local recurrences in the follow-up period. Thirteen patients were treated with adjuvant RT. The six patients that were treated with ECT alone were tumor-free and alive 5 years after treatment. There was one serious adverse event reported; aspiration after treatment of a tongue base tumor. The tumor-specific 5-year survival was 75%. The QoL outcome 1 year after ECT showed a significant increase in problems with senses (taste, smell), speech, mouth opening and xerostomia. The QoL outcome also showed worse outcome in the smoking patients regarding speech, in the patients receiving adjuvant RT regarding mouth dryness and swallowing and in the patients with non-tongue oral cavity cancer regarding need for painkillers.

28 December 2010 in Acta Oto-Laryngologica
Verified
Journal Article
Closed access
PDF file
FLFredrik J. Landström
Fredrik J. Landström
CNChrister O.S. Nilsson
Christer O.S. Nilsson
JRJohan A. Reizenstein
Johan A. Reizenstein
KNKent Nordqvist
Kent Nordqvist
GAGun-Britt Adamsson
Gun-Britt Adamsson
ALA. Lennart Löfgren
A. Lennart Löfgren
Conclusion: Electroporation therapy appears to be a safe treatment achieving excellent local tumor control and very good functional results in our study and it should be further clinically evaluated. Objectives: The objectives of this study were to assess local tumor control, survival, and effects on speech and eating after treatment of tongue cancer with electroporation therapy, a new local therapeutic modality. In this approach intracellular accumulation of a chemotherapeutic agent is achieved by using a locally applied electrical field. Methods: Fifteen patients with primary T1 and T2 oral tongue cancer were treated with electroporation therapy with intratumorally administered bleomycin. Postoperative radiotherapy was performed when the tumor infiltration was 5 mm or more. The follow-up time was 24 months for the surviving patients and 20.4 months overall. The effects on eating and speech were assessed using the PSS-HN scale and voice recordings. Results: No local recurrence was recorded in any patient during the follow-up. Three patients died, two from progressive regional disease. Of the 12 surviving patients, 2 patients had regional recurrence and 10 patients including the 5 patients treated with EPT alone were tumor-free both locally and regionally at the last follow-up. The functional outcome for speech and eating were very good.

15 December 2014 in Acta Oto-Laryngologica
Verified
Journal Article
Closed access
PDF file
FLFredrik J. Landström
Fredrik J. Landström
JRJohan A. Reizenstein
Johan A. Reizenstein
CNChrister O. S. Nilsson
Christer O. S. Nilsson
MBMathias Von Beckerath
Mathias Von Beckerath
ALA. Lennart Löfgren
A. Lennart Löfgren
CMClaes Möller
Claes Möller
Conclusion: Electrochemotherapy (ECT) is an efficacious treatment. It should, however, be used with some caution in the treatment of head and neck cancer. Objectives: To assess local tumor control, safety, survival, and functional outcome after treatment of cancer in the head and neck region with ECT. Methods: Four patients with primary T2 cancer of the oral cavity or oropharynx and one patient with a metastasis of renal cancer in the masseter muscle were treated with ECT with intratumorally administered bleomycin. Control biopsies were carried out 2 months after treatment. Postoperative radiotherapy was performed based on tumor T-stage and the depth of tumor infiltration. Serious adverse events and treatment malfunctions were recorded. The follow-up time was 24 months for the surviving patients and 20 months overall. The PSS-HN scale was used to assess the functional outcome. Results: No local recurrence was recorded in any patient during the follow-up. However, only one patient was treated with ECT alone. There were four serious adverse events: one nearly lethal bleeding, two cases of osteoradionecrosis, and a fistula. One patient died from distant metastasis. The other patients were tumor-free both locally and overall at 24 months. The median functional outcome in all parameters was worse 1 year after treatment.

26 May 2014 in Acta Oto-Laryngologica
Verified
Journal Article
Closed access
PDF file
MBMathias P. von Beckerath
Mathias P. von Beckerath
JRJohan A. Reizenstein
Johan A. Reizenstein
ABAttila L. Berner
Attila L. Berner
KNKent W.O. Nordqvist
Kent W.O. Nordqvist
FLFredrik J. Landström
Fredrik J. Landström
CMClaes G. Möller
Claes G. Möller
Conclusion: Photodynamic therapy (PDT) is a viable and safe option for early laryngeal cancer that would be less suitably treated with radiation or trans-oral laser surgery (TLS). The cure rates with PDT appear to be comparable to those of conventional therapy, and the voice outcomes are also comparable. In the case of many sarcomas, PDT appears to be an organ- and function-sparing therapy, although it is more costly than other treatments. Objectives: The aim of this study was to show the results of PDT when it is used as a primary treatment of early laryngeal cancer. Methods: We studied the results of PDT when used as a primary treatment. We looked at survival, effect on tumor, side effects, voice, and costs. Results: The follow-up period was a median of 59 months. Nine of 10 patients were cured of their laryngeal cancer. PDT alone cured seven patients. All four of the sarcomas were cured using temoporfin. Two of three tumors that involved the anterior commissure were cured using only interstitial illumination with PDT. No serious side effects were noted. The patient’s voices were improved after treatment in 5 of 10 cases, and none had a worsened voice.

1 November 2015
Verified
Journal Article
Closed access
FLFredrik Landström
Fredrik Landström
MIMikael Ivarsson
Mikael Ivarsson
ASAnita Koskela Von Sydow
Anita Koskela Von Sydow
AMAnders Magnuson
Anders Magnuson
MBMathias Von Beckerath
Mathias Von Beckerath
CMClaes Möller
Claes Möller